Advertisement
OtherNEUROPHARMACOLOGY

Dynorphin Block of N-Methyl-d-Aspartate Channels Increases with the Peptide Length

Li Chen and Li-Yen Mae Huang
Journal of Pharmacology and Experimental Therapeutics March 1998, 284 (3) 826-831;

Abstract

We examined the non-opioid actions of various forms of dynorphin A (DynA) on N-methyl-d-aspartate (NMDA) receptor channels in isolated rat trigeminal neurons using the whole-cell patch recording technique. All the dynorphins tested blocked NMDA-activated currents. The blocking actions were voltage-independent. The IC50 was 0.26 μM for DynA(1-32), 6.6 μM for DynA(1-17) 7.4 μM for DynA(1-13), 42.0 μM for DynA(1-10). DynA(1-8) had no detectable blocking action on NMDA responses. Thus, the IC50s of dynorphins for NMDA receptors increased 160-fold as the length of the peptides decreased from 32 to 10 amino acids. Amidation of dynorphins dramatically reduced their IC50s and eliminated the large difference in the IC50s of various lengths of dynorphins. The reduction in the IC50s of dynorphin amides could not be explained by the resistance of the peptides to enzymatic degradation. Our observations suggest that peptide processing affects dynorphin blocking actions on NMDA responses. The positively charged residues, lengths of the peptides and amidation may contribute to their affinities for NMDA receptors.

The spinal trigeminal nucleus caudalis (the medullary dorsal horn) is the major center involved in processing nociceptive and temperature information. Cells in this region receive inputs from afferent fibers innervating the face and oral cavity. At the same time, they are subjected to inhibitory controls of the descending pathways and local circuits. Projection neurons then integrate the information and relay it to the thalamus and somatosensory cortex. Glutamate and aspartate are abundantly expressed in dorsal horn neurons (Magnusson, et al., 1986). These amino acids activate both NMDA and non-NMDA receptors and serve as the major excitatory transmitters mediating the synaptic transmission in the nociceptive pathway (Gu and Huang, 1991;Gu and Huang, 1994; Salt and Hill, 1982; Zhang, et al., 1996).

Dynorphins and the mRNA encoding the dynorphin gene, preprodynorphin, are found in the superficial dorsal horns of the spinal cord and of the caudal medulla (Cruz and Basbaum, 1985; Nishimori, et al., 1988; Ruda, et al., 1988). In response to high frequency stimulation of afferent fibers, DynA is released in the laminae I and V-VI of the dorsal horns (Hutchison, et al., 1990). The actions of dynorphins are mostly inhibitory. They reduce the firing frequency of dorsal horn cells and lengthen the latency of tail flick reflexes evoked by noxious electrical, mechanical and thermal stimuli (Caudle and Isaac, 1988; Hope et al., 1990; Knox and Dickenson, 1987; Millan, 1989; Yaksh, 1993). In addition to the inhibitory effects, dynorphins sometimes exert excitatory actions on dorsal horn cells. For instance, dynorphins enhance the glutamate-evoked firing of spinothalamic tract neurons (Willcocksonet al., 1986), and enlarge the receptor field or increase the activity of dorsal horn neurons in response to C-fiber or mechanical stimulation (Hylden et al., 1991; Knox and Dickenson, 1987).

Not all the dynorphin actions involve κ-opioid receptors: many are insensitive to high doses of the opioid receptor antagonist, naloxone; some can be mimicked by non-opioid peptide, Des-Tyr DynA (Faden, 1990;Hooke, et al., 1995; Hylden, et al., 1991; Knox and Dickenson, 1987; Vanderah, et al., 1996; Willcockson,et al., 1986). We recently found that dynorphins reduce NMDA-activated currents (INMDA) in trigeminal neurons (Chen et al., 1995a,1995b). The actions cannot be reversed by naloxone or by the κ-opioid receptor antagonist, norBNI. In addition, dynorphins reduce the opening probability of single NMDA channels in cell-free patches. These observations have led us to suggest that dynorphins interact directly with NMDA receptors (Chenet al., 1995a, 1995b). We also explored the site of action for dynorphin. Since dynorphin (1-17) changes neither the EC50 of NMDA nor the potentiating effect of glycine, the dynorphin does not appear to interact with the agonist recognition sites on NMDA receptors. The binding site for dynorphin is distinct from the sites for H+, Zn++ or Mg++ because the blocking action of dynorphin (1-17) remains unchanged in different pH or Zn++ solutions and the effect of dynorphin is voltage-independent. Because the IC50 of dynorphin for NMDA receptors is lowered substantially when the disulfide bonds in NMDA receptors are reduced by DTT, we suggest that dynorphin may interact with a site conformationally linked with the redox site(s) on NMDA receptors (Chen, et al., 1995a).

As with many neuropeptides, dynorphins are made from a large precursor molecule, i.e., prodynorphin. In the brain and spinal cord, prohormone convertases cleave prodynorphin at the dibasic residues to generate DynA(1-32), A(1-17) and DynB(1-29) (Cone et al., 1983; Fricker and Devi, 1995; Sonders and Weber, 1987). Dynorphin converting enzyme then processes DynA(1-17) at the single Arg residue to produce DynA(1-9) and DynA(1-8) (Devi et al., 1991). DynA(1-9) is further converted to DynA(1-8) by caboxylpeptidase E in the secretory granules before releasing from cells. Because the processing enzymes are differentially expressed in the various brain regions, different lengths of dynorphins are produced in different levels in these locations (Dickerson and Noël, 1991). Although posttranslational processing has been recognized as an important regulatory step in dynorphin biosynthesis, the physiological consequence of this processing has not been fully explored. We therefore studied the actions of various forms of DynA on NMDA responses in trigeminal neurons. We found that different dynorphins exert similar nonopioid blocking actions on NMDA-activated currents. However, their apparent affinities, i.e.,IC50s, for NMDA receptors differ by as much as 200-fold. Positive charges on the dynorphin molecules and conformation of the peptides appear to be important in determining the affinities of these peptides.

Materials and Methods

Dissociated trigeminal neurons were isolated from 10- to 15-day-old Long Evans rats using the method described (Gu and Huang, 1991; Huang, 1989). In brief, the lower medulla was removed and put in an ice-cold, oxygenated dissecting solution. The solution consisted of (mM) NaCl (120), KCl (10), CaCl2 (1), MgCl2 (6), glucose (10) and PIPES (10) (pH = 7.15) (osmolarity = 305-315 mosm). The tissue was cut into 300 μm thick horizontal slices with a vibratome slicer and incubated in the dissecting solution at 34.5°C for 30 min. The slices were then put in a dissecting solution that contained 2.5 mg/ml papain (Sigma P3250). After 40- to 60-min incubation period, the tissue was washed with enzyme-free dissecting solution and stored at room temperature. Before an experiment, the spinal trigeminal nuclei in the caudal medulla were isolated from a tissue slice with a scalpel. Neurons were isolated by triturating the tissue with a series of fire-polished Pasteur pipettes.

Whole-cell currents were recorded using the patch clamp technique. The external solution contained (mM) NaCl (140), KCl (4), glucose (10), HEPES (10) (pH = 7.4) and CaCl2 (2). Experiments were performed in 0 Mg++ and 2 μM glycine. Because the treatment of the AMPA receptor antagonist, CNQX, did not change our results, most experiments were conducted in the absence of a non-NMDA receptor antagonist. The internal solution contained (mM) Cs methanesulfonate (125), CsCl (15), glucose (10), BAPTA (10), CaCl2 (1) and HEPES (10) (pH = 7.2). Mg-ATP (5 mM), leupeptin (400 μM) (Sigma Chemical Co., St. Louis, MO) and GTP (200 μM) were added to the internal solution to prevent the rundown. All chemicals are ultrapure grade. Dynorphins (Peninsula Lab, Belmont, CA) were disolved in the external solution immediately before use.

NMDA was delivered to the recorded cell using the fast perfusion technique (Gu and Huang, 1991). The solution exchange was accomplished in 10 msec. Each NMDA application lasted for 1.5 sec. To avoid excessive desensitization or rundown of the INMDAs caused by repeated NMDA applications, we washed NMDA out completely after each application and waited 2 to 3 min before another NMDA application. With this precaution, INMDAs decayed rather slowly during the course of experiments. To take into account the current decay, two NMDA responses were recorded in a dynorphin solution and the responses were compared with the NMDA responses taken immediately before the dynorphin application.

The currents were sampled at 200 μsec and signals were filtered at 2 kHz. The χ2 method was used to analyze the dose-inhibition curves. The average data values are expressed as mean ± S.E.

A Beckman reverse-phase column (0.46 × 25 cm, ODS, C18) was used for the HPLC analysis. The column was preequilibrated with .1% aqueous trifluoracetic acid. The peptides were eluted with a linear 0 to 60% acetonitrile gradient. The eluted material was monitored at 230 nm with a Beckman Gold System 406.

Results

The IC50s of dynorphins increase as the peptides become shorter.

Figure 1shows the effect of various dynorphins on NMDA responses in trigeminal neurons. At the holding potential of -70 mV, NMDA (100 μM) activated large inward currents (INMDAs). After incubating cells in dynorphin-containing external solution for 2 min, NMDA responses were tested again. Dynorphins reduced the INMDAs (fig. 1A). The block was rapid and could be readily reversed when dynorphins were washed out (Chen et al., 1995a, 1995b) (data not shown). Opioid receptors were not involved because the inhibition could not be reversed by naloxone or by nor-BNI (data not shown). The dynorphin blocking effect was observed in all of the cells that responded to NMDA.

Figure 1
Figure 1

The apparent affinities of dynorphins for NMDA receptors change with the lengths of the peptides. A, The block of NMDA responses by three naturally occurring dynorphins. NMDA (100 μM) activated large inward currents at the holding potential of -70 mV. DynA(1-32), at 0.25 μM, reduced the peak INMDA by 50%; DynA(-17), at 5 μM, blocked the current by 30%. DynA(1-8), even at 100 μM, had no effect on the NMDA response. The data are from three different cells. B, Dose inhibition curves of various dynorphins. The solid lines are theoretical fits of the data using the equation, I = Io[IC50]n/([IC50]n + [DynA]n), where Io is the peak INMDA immediately before the dynorphin treatment. The Hill coefficient n was set at 1.0. IC50 was .26 μM for DynA(1-32), 6.6 μM for DynA(1-17), 7.4 μM for DynA(1-13) and 42.0 μM for DynA(1-10).

When the blocking actions of the three naturally occurring dynorphins,i.e., DynA(1-32), DynA(1-17) and DynA(1-8), were studied, we found that the potency of the dynorphins depended on their lengths (fig. 1A). The longer the dynorphin, the more potent was the block. The dose-inhibition curves of these dynorphins were similar in shape (Hill coefficient = 1) (fig. 1B). But, the IC50 of the block changed dramatically with the length of the molecules. The IC50 was 42.0 ± 6.0 (n = 5) μM for DynA(1-10), 7.4 ± 1.9 μM (n = 6) DynA(1-13), 6.6 ± 1.1 μM (n = 5) for DynA(1-17) and 0.26 ± 0.03 (n = 7) μM for DynA(1-32). Thus, the IC50s decreased or the apparent affinities increased 160-fold as the length of the dynorphins increased from 10 to 32 amino acids. DynA(1-8), even at 100 μM, had no detectable blocking action on NMDA responses (fig. 1A). The IC50 of DynA(1-13) and of DynA(1-17) obtained here (fig. 1B) are much larger than those reported in our previous report (Chen et al., 1995b). The reason is that amidated forms of DynA(1-13) and of DynA(1-17) were used before. The difference between the carboxyl and amidated forms of dynorphins will be discussed later. The effect of DynB (1-13) on NMDA currents was also tested; DynB blocked NMDA current with an IC50 of 38.8 ± 6.8 μM (n = 3).

The blocking actions of various dynorphins are voltage-independent.

We found that the block of NMDA responses by DynA(1-32) was voltage independent (Chen et al., 1995b). To determine if shorter dynorphins had the similar blocking property, we examined the action of DynA(1-10) at different membrane potentials. The current-voltage relationship of the peptide was given in figure2A. DynA(1-10) blocked INMDA to a similar extent as the membrane potentials changed from -80 to +60 mV (fig. 2). Thus, despite a 160-fold difference in the apparent affinities, DynA(1-32) and DynA(1-10) both exerted voltage-independent actions on NMDA receptors.

Figure 2
Figure 2

The dynorphin block is voltage independent. A, The peak current voltage relationships in the absence and in the presence of 30 μM DynA(1-10). The data points were normalized with respect to the current measured at -60 mV in the absence of dynorphins. The data points are averaged from 6 to 10 cells. The S.E., when larger than the data points, are indicated by error bars. The solid lines are polynomial fits of the data. B, The same data as in A were replotted as % of inhibition at different membrane potentials. The reduction of peak INMDAs by DynA(1-10) was voltage-independent.

Amidation of dynorphins increases the apparent affinity of the peptides for NMDA-receptor channels.

To find out if the negative charge at the C-terminus of the dynorphins was important in determining their affinities for NMDA-receptor channels, we compared the IC50 of dynorphins and dynorphin amides. The IC50 of DynA(1-17) amide was 1.7 ± 0.3 μM (n = 6), which was 4-fold lower than that of DynA(1-17) (fig. 3). The difference between the IC50 of DynA(1-10) amide and of DynA(1-10) was even larger (fig. 3). The IC50 of DynA(1-10) amide was 1.7 ± 0.2 μM (n = 5); the IC50 of DynA(1-10) was 42.0 ± 6.0 μM (n = 5). Amidation resulted in a ∼25-fold reduction in the IC50. Furthermore, in sharp contrast to the large differences in the IC50 of the unamidated dynorphins, the IC50s of various dynorphin amides were very similar. Thus, the negative charge at the C-terminus of the dynorphins has a profound effect on their affinities for NMDA receptor channels.

Figure 3
Figure 3

Amidation of dynorphins increases the affinity and abolishes the differences in IC50s of different dynorphins. A, At similar concentrations, amidated dynorphins exerted a stronger block on NMDA responses. DynA(1-17), at 2.5 μM, blocked NMDA-activated current by 27%, whereas DynA(1-17) amide, at 2.0 μM, reduced the current by 62%. At 5 μM, DynA(1-10) decreased the NMDA response by 17%, but DynA(1-10) amide decreased the response by 73%. B, Dose-inhibition curves of amidated dynorphins. Despite large differences between the IC50 of DynA(1-17) and of DynA(1-10), the IC50s of DynA(1-17) amide, and DynA(1-10) amide were the same (1.7 μM). The dose-inhibition curve for DynA(1-17) amide was fit with a Hill coefficient of 0.93, the rest of the curves were fit with a Hill coefficeint of 1.0.

Resistance to enzymatic degradation cannot explain the large reduction in the IC50 of the dynorphin amides.

It is often suggested that α-amidation renders a peptide less susceptible to exopeptidase degradation (McKnight et al., 1983). To find out if this characteristic contributed to the impressive reduction in the IC50 of the amidated dynorphins, we carried out two types of experiments. First, we determined the degradation products in our dynorphin or dynorphin amide solutions using the HPLC. No extra degradation products were found in the HPLC profile of DynA(1-10) even after the peptide had been incubated in the external solution for an extended period (>60 min) (fig. 4). Second, we examined the IC50 of DynA(1-10) in an external solution that contained a cocktail of peptidase inhibitors (fig.5). The cocktail, which consisted of 20 μM bestatin, 10 μM captopril, 0.3 μM thiorphan and 2 mM Leu-leucine, is known to block a broad spectrum of peptidases (McKnightet al., 1983). In the presence of the peptidase inhibitors, the IC50 of DynA(1-10) was 46.2 ± 6.7 μM (n = 4), which was not significantly different from the IC50 obtained in the absence of inhibitors (i.e., 42.0 ± 6.0 μM, n = 5) (P ≥ .65). From these two experiments, we conclude that resistance to enzymatic degradation cannot explain the large reduction in the IC50s of dynorphin amides.

Figure 4
Figure 4

The HPLC profiles of DynA(1-10) and DynA(1-10) amide. No degradation product was seen in either profile.

Figure 5
Figure 5

The increased affinity for dynorphin amides is not due to their resistance to enzymatic degradation. The IC50of DynA(1-10), in the presence of peptidase inhibitors, was 46.2 ± 6.7 μM (n = 4); the IC50 obtained in the absence of inhibitors was 42.0 ± 6.0 μM (n = 5). The difference was not statistically significant.

DynA (1-10) and DynA(1-10) amide compete for the same binding site on NMDA-receptor channels.

We also determined whether DynA (1-10) and DynA (1-10) amide acted on the same receptor site. The IC50 of DynA(1-10) amide was obtained in the presence of 40 μM DynA(1-10). If the two peptides competed for the same binding site, the IC50 of DynA(1-10) amide is expected to increase. This was indeed the case. The IC50 of DynA(1-10) amide changed from 1.7 ± 0.2 μM to 3.6 ± 0.3 μM (n = 5) when DynA(1-10) was added to the external solution (fig.6). We further determined if the change in the IC50 could be quantitatively accounted for by a single site model, i.e. the binding of one molecule excludes the binding of the second molecule. According to the model, the IC50 of DynA(1-10) amide in the presence of DynA(1-10), i.e., IC50-amide*, isIC50­amide*=IC50­amide (1+[DynA10]/IC50­DynA10) where IC50-amide is the IC50 of DynA(1-10) amide without DynA(1-10), [DynA10] is the concentration and IC50-DynA10is the IC50 of DynA(1-10). Using IC50-DynA10 = 42 μM, [DynA10] = 40 μM, the calculated IC50-amide* is 3.3 μM, in good agreement with our experimental results.

Figure 6
Figure 6

DynA(1-10) and DynA(1-10) amide compete for the same binding site. The effects of DynA(1-10) amide and DynA(1-10) amide plus 40 μM DynA(1-10) on NMDA responses were examined. In the presence of DynA(1-10), the IC50 of DynA(1-10) amide changed from 1.7 μM to 3.6 μM. The data are the average values from five cells.

Discussion

We confirmed and extended our previous observation that dynorphins directly interact with NMDA receptors (Chen et al., 1995a,1995b). The apparent affinities of dynorphins depend on the length of peptides. In addition, we found that α-amidation not only increases the dynorphin apparent affinities for NMDA receptors, but also abolishes the large differences in the affinities of DynA(1-17), DynA(1-13) and DynA(1-10) (fig. 3). The lack of degradation products in the HPLC profile (fig. 4) and the insensitivity of the IC50 of DynA(1-10) to peptidase inhibitors (fig.5) suggest that the high affinities of dynorphin amides do not result from their resistance to enzymatic degradation. Rather, our results are consistent with the idea that amidation eliminates the negative charge at the C-terminus of the dynorphins, rendering them better able to interact with NMDA receptors.

The charge group at the C-terminus is not the only determinant for the binding of dynorphins. The positively charged amino acids, Arg and Lys might facilitate the interactions with NMDA receptors. The amino acid sequences and charge distributions of dynorphins are given in figure7. Among the dynorphins tested, DynA(1-32), with three Arg and two Lys residues extended beyond Gln17, has the highest affinity for NMDA receptors despite its terminal COO− group (fig.1). DynA(1-17) and DynA(1-13), with the same number of Arg and Lys groups, have the same IC50. Without the two Lys groups toward the C-terminal end, the apparent affinity of DynA(1-10) is further reduced by ∼7 fold (fig. 3). Eliminating one more Arg causes DynA(1-8) to lose its ability to bind NMDA receptors. Without any Arg or Lys, Leu-enkephalin and Leu-enkephalin amide have almost no affinity for NMDA receptors (fig. 7). It is conceivable, however, that the conformation of dynorphins derived from the positive charges, rather than the positive charges themselves, is the major determinant for the interaction between dynorphins and NMDA receptors. We therefore conclude that the amidation, the positively charged groups and the lengths of dynorphins, which contribute to the three-dimensional conformation of the molecules, are important in determining their binding affinities for NMDA receptors.

Figure 7
Figure 7

The amino acid sequences, charge distributions and IC50 of dynorphin-related peptides. The positively charged residues are shown in bold letters. The cell number studied for each dynorphin is indicated in parentheses.

Because the dynorphin block of NMDA receptor channels occurs at high opioid concentrations (>100 nM), it may argue that this nonopioid effect would not be physiologically important. This argument, however, ignores the anatomical relationship between opioid peptide-containing terminals and opioid receptors. Mu (μ)- and κ-opioid receptors primarily localize on somatodendritic membrane; many are found at extrasynaptic sites, away from opioid-containing terminals (Arvidssonet al., 1995a, 1995b; Svingos et al., 1996). These observations suggest that opioids, once released, will travel considerable distances before reaching opioid receptors. It is therefore not surprising to find opioid receptors displaying high affinity for their ligands. In contrast, glutamate receptors are found to associate with synaptic terminals (Martin et al., 1993;Siegel et al., 1994). Opioids and substance P are found to colocalize in nerve terminals (Tashiro et al., 1987; Weiheet al., 1986), a majority of which may be glutamate-positive (Battaglia and Rustioni, 1988). Using known dynorphin concentration in secretory vesicles, we estimated that the dynorphins at postsynaptic NMDA receptors would exceed micromolars (Chen et al., 1995a), a concentration range that could affect NMDA responses.

Bioactive opioid peptides are derived from large precursors (i.e., POMC, proenkephlin and prodynorphin) that undergo posttranslational processing. One distinct feature of peptide processing is tissue specificity (Cone et al., 1983; Fricker and Devi, 1995; Sonders and Weber, 1987). Expressing in different levels, processing enzymes cleave prodynorphin into dissimilar sets of dynorphin molecules in different tissues. The concentrations of various dynorphins, therefore, vary markedly among brain regions. In the caudate, DynA(1-8) is ∼7 times more concentrated than DynA(1-17). The [DynA(1-8)/DynA(1-17)] ≈ 2 in the hypothalamus and ≈ 1 in the hippocampus (Cone et al., 1983; Sonders and Weber, 1987). In the spinal cord, the ratio is reversed, that is, DynA(1-17) is 1.25 to 2.8 times more abundant than DynA(1-8) (Cone et al., 1983; Sonders and Weber, 1987). A physiological consequence of the varying dynorphin concentration ratios can be deduced from our results. Because DynA(1-17) has a much higher affinity for NMDA receptors than DynA(1-8), the nonopioid blocking actions of dynorphins would be prominent in the spinal cord, but less so in the caudate. Nevertheless, the nonopioid effect may not be negligible in other regions of the brain because a substantial amount of DynA(1-17) is produced in those areas (Cone et al., 1983; Sonders and Weber, 1987). Thus, because different dynorphins have different affinities for NMDA receptors (fig. 1) and possess different metabolic stability (Corbett et al., 1982), the posttranslational processing of dynorphins is a likely mechanism used for regulating the function of the peptides.

In addition to the tissue variability, processing of opioid peptide precursors can be altered temporally (Dickerson and Noël, 1991). Although the effect of tissue injury on opioid processing has yet to be examined, plastic changes in dynorphin distribution in the spinal and trigeminal dorsal horns following inflammation or arthritis have been observed. Compared with other opioid peptides, dynorphins are particularly sensitive to tissue injury. Chronic arthritic inflammation raises the prodynorphin and the level of dynorphin synthesis up to 2- to 4-fold in the dorsal horns, whereas proenkephalin increases only moderately (∼50%) (Kajander et al., 1990; Millan, 1993;Ruda et al., 1988; Weihe et al., 1989). Under normal physiological conditions, the dynorphin concentrations probably are not high enough to saturate the non-opioid effect of dynorphins (fig. 1) (Chen et al., 1995b). An increase in dynorphin expression after tissue injury would dramatically increase its blocking action on NMDA responses. Furthermore, the mRNAs encoding the prohormone convertases I and II are found to increase rapidly after electroconvulsive treatment in the hippocampus (Bhat et al., 1993). Because tissue injury is always accompanied with intensive electrical activities, the relative concentration ratios of dynorphins are likely to change. This would alter the nonopioid actions of dynorphins, further contributing to the plasticity of dynorphin functions.

Acknowledgments

The authors thank Dr. S. Liu for the assistance of HPLC analyses and S. Y. Wong for cell preparation.

Footnotes

  • Send reprint requests to: Dr. Li-Yen Mae Huang, Marine Biomedical Institute, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555-1069.

  • ↵1 The work is supported by National Institutes of Health Grants NS30045 and NS11255 and a Human Frontier Science Program grant to L.-Y.M.H.

  • Abbreviations:
    DynA
    dynorphin A
    NMDA
    N-methyl-d-aspartate
    DTT
    diehiothreitol
    • Received September 25, 1997.
    • Accepted November 24, 1997.

References

  1. ↵
    1. Arvidsson U,
    2. Riedl M,
    3. Chakrabarti S,
    4. Lee JH,
    5. Nakano AH,
    6. Dado RJ,
    7. Loh HH,
    8. Law PY,
    9. Wessendorf MW,
    10. Elde R
    (1995a) Distribution and targeting of a mu-opioid receptor (MOR1) in brain and spinal cord. J Neurosci 15:3328–3341.
    OpenUrlAbstract
  2. ↵
    1. Arvidsson U,
    2. Riedl M,
    3. Chakrabarti S.,
    4. Vulchanova L,
    5. Lee JH,
    6. Nakano AH,
    7. Lin XQ,
    8. Loh HH,
    9. Law PY,
    10. Wessendorf MW,
    11. Elde R
    (1995b) The kappa-opioid receptor is primarily postsynaptic—combined immunohistochemical localization of the receptor and endogenous opioids. Proc Natl Acad Sci USA 92:5062–5066.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Battaglia G,
    2. Rustioni A
    (1988) Coexistence of glutamate and substance P in dorsal root ganglion neurons of the rat and monkey. J Comp Neurol 277:302–312.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Bhat RV,
    2. Tausk FA,
    3. Baraban JM,
    4. Mains RE,
    5. Eipper BA
    (1993) Rapid increases in peptide processing enyzme expression in hippocampal neurons. J Neurochem 61:1315–1322.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Caudle RM,
    2. Isaac L
    (1988) Influence of dynorphin (1-13) on spinal reflexes in the rat. J Pharmacol Exp Ther 246:508–513.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Chen L,
    2. Gu Y,
    3. Huang L-YM
    (1995a) The mechanism of action for the block of NMDA receptor channels by the opioid peptide dynorphin. J Neurosci 15:4602–4611.
    OpenUrlAbstract
  7. ↵
    1. Chen L,
    2. Gu Y,
    3. Huang L-YM
    (1995b) The opioid peptide dynorphin directly blocks NMDA-receptor channels in the rat. J Physiol 482:575–581.
    OpenUrlPubMed
  8. ↵
    1. Cone RI,
    2. Weber E,
    3. Barchas JD,
    4. Goldstein A
    (1983) Regional distribution of dynorphin and neo-endorphin peptides in rat brain, spinal cord, and pituitary. J Neurosci 3:2146–2152.
    OpenUrlAbstract
  9. ↵
    1. Corbett AD,
    2. Paterson SJ,
    3. McKnight AT,
    4. Magnan J,
    5. Kosterlitz H
    (1982) Dynorphin1-8 and Dynorphin1-9 are ligands for the κ-subtype of opiate receptor. Nature 299:79–81.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Cruz L,
    2. Basbaum AI
    (1985) Multiple opioid peptides and the modulation of pain: immunohistochemical analysis of dynorphin and enkephalin in the trigeminal nucleus caudalis and spinal cord of the cat. J Comp Neurol 240:331–348.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Devi L,
    2. Gupta P,
    3. Fricker LD
    (1991) Subcellular localization, partial purification, and characterization of a dynorphin processing endopeptidase from bovine pituitary. J Neurochem 56:320–329.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Fricker LD
    1. Dickerson IM,
    2. Noël G
    (1991) Tissue-specific peptide processing. in Peptide Biosynthesis and Processing, ed Fricker LD (CRC Press, Boca Raton, FL), pp 71–109.
  13. ↵
    1. Faden AI
    (1990) Opioid and nonopioid mechanism may contribute to dynorphin’s pathophysiological actions in spinal cord injury. Ann Neurol 27:67–74.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Tseng LF
    1. Fricker L,
    2. Devi L
    (1995) Enzymes involved in opioid peptide biosynthesis. in The Pharmacology of Opioid Peptides, ed Tseng LF (Hardwood Academic Publishers, Amsterdam), pp 87–107.
  15. ↵
    1. Gu Y,
    2. Huang L-YM
    (1991) Block of kainate receptor channels by Ca2+ in isolated spinal trigeminal neurons of rat. Neuron 6:777–784.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Gu Y,
    2. Huang L-YM
    (1994) Modulation of glycine affinity for NMDA receptors by extracellular Ca2+ in trigeminal neurons. J Neurosci 14:4561–4570.
    OpenUrlAbstract
  17. ↵
    1. Hooke LP,
    2. He L,
    3. Lee NM
    (1995) [Des-Tyr1]dynorphin A-(2-17) has naloxone-insensitive antinociceptive effect in the writhing assay. J Pharmacol Exp Ther 273:802–807.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Hope PJ,
    2. Fleetwood-Walker SM,
    3. Michell R
    (1990) Distinct antinociceptive actions mediated by different opioid receptors in the region of lamina I and laminae II-V of the dorsal horn of the rat. Br J Pharmacol 10:477–483.
    OpenUrl
  19. ↵
    1. Huang L-YM
    (1989) Calcium channels in isolated rat dorsal horn neurones including labelled spinothalamic and trigeminothalamic cells. J Physiol 411:161–177.
    OpenUrlPubMed
  20. ↵
    1. Hutchison WD,
    2. Morton CR,
    3. Terenius L
    (1990) Dynorphin A: in vivo release in the spinal cord of the cat. Brain Res 532:299–306.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Hylden JLK,
    2. Nahin RL,
    3. Traub RJ,
    4. Dubner R
    (1991) Effects of spinal kappa-opioid receptor agonists on the responsiveness of nociceptive superficial dorsal horn neurons. Pain 44:187–193.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Kajander KC,
    2. Sahara Y,
    3. Iadarola MJ,
    4. Bennett GJ
    (1990) Dynorphin increases in the dorsal spinal cord in rats with a painful peripheral neuropathy. Peptides 11:719–728.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Knox RJ,
    2. Dickenson AH
    (1987) Effects of selective and non-selective κ-opioid receptor agonists on cutaneous C-fibre-evoked responses of rat dorsal horn neurons. Brain Res 415:21–29.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Magnusson KR,
    2. Larson AA,
    3. Madl JE,
    4. Altschuler RA,
    5. Beitz AJ
    (1986) Co-localization of fixative-modified glutamate and glutaminase in neurons of the spinal trigeminal nucleus of the rat: An immunohistochemical and immunoradiochemical analysis. J Comp Neurol 247:477–490.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Martin LJ,
    2. Blackstone CD,
    3. Levey AI,
    4. Huganir RL,
    5. Price DL
    (1993) AMPA glutamate receptor subunits are differentially distributed in rat brain. Neuroscience 53:327–358.
    OpenUrlCrossRefPubMed
  26. ↵
    1. McKnight AT,
    2. Corbett AD,
    3. Kosterlitz H
    (1983) Increase in potencies of opioid peptides after peptidase inhibition. Eur J Pharmacol 86:393–402.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Millan MJ
    (1989) Kappa-opioid receptor-mediated antinociception in the rat. I. Comparison on mu- and kappa-antinociception against noxious thermal, pressure and electrical stimuli. J Pharmacol Exp Ther 251:334–351.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. Herz A
    1. Millan MJ
    (1993) Multiple opioid systems and chronic pain. in Opioids II, Handbook of Experimental Pharmacology, ed Herz A (Springer-Verlag, Berlin), 104/I:127–162.
  29. ↵
    1. Nishimori T,
    2. Moskowitz MA,
    3. Uhl GR
    (1988) Opioid peptide gene expression in rat trigeminal nucleus caudalis neurons: Normal distribution and effects of trigeminal deafferentation. J Comp Neurol 274:142–150.
    OpenUrlCrossRefPubMed
  30. ↵
    1. Ruda MA,
    2. Iadarola MJ,
    3. Cohen LV,
    4. Young WS
    (1988) In situ hybridization histochemistry and immunocytochemistry reveal an increase in spinal dynorphin biosynthesis in a rat model of peripheral inflammation and hyperalgesia. Proc Natl Acad Sci USA 85:622–626.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    1. Salt TE,
    2. Hill RG
    (1982) Pharmacological differentiation between responses of rat medullary dorsal horn neurons to noxious mechanical and noxious thermal cutaneous stimuli. Brain Res 263:167–171.
  32. ↵
    1. Siegel SJ,
    2. Brose N,
    3. Janssen WG,
    4. Gasic GP,
    5. Jahn R,
    6. Heinemann SF,
    7. Morrison JH
    (1994) Regional, cellular, and ultrastrucutral distribution of N-methyl-D-aspartate receptor subunit 1 in monkey hippocampus. Proc Natl Acad Sci USA 91:564–568.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    1. Sonders M,
    2. Weber E
    (1987) Distribution pattern of metorphamide compared with other opioid peptides from proenkephalin and prodynorphin in the bovine brain. J Neurochem 49:671–680.
    OpenUrlCrossRefPubMed
  34. ↵
    1. Svingos AL,
    2. Moriwaki A,
    3. Wand JB,
    4. Uhl GR,
    5. Pickel VM
    (1996) Ultrastrucutral immunocyotchemical localization of μ-opioid receptors in rat nucleus accumbens: Extrasynaptic plasmalemmal distribution and association with Leu5-enkephalin. J Neurosci 16:4162–4173.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. Tashiro T,
    2. Takahashi O,
    3. Satoda T,
    4. Matsushima R,
    5. Mizuno N
    (1987) Immunohistochemical demonstration of coexistence of enkephalin- and substance P-like immunoreactivities in axonal components in the lumbar segments of cat spinal cord. Brain Res 424:391–395.
    OpenUrlCrossRefPubMed
  36. ↵
    1. Vanderah TW,
    2. Laughlin T,
    3. Lashbrook JM.,
    4. Nichols ML,
    5. Wilcox GL,
    6. Ossipov MH,
    7. Malan TP,
    8. Porreca F
    (1996) Single intrathecal injections of dynorphin a or des-tyr-dynorphins produce long-lasting allodynia in rats—blockade by MK-801 but not naloxone. Pain 68:275–281.
    OpenUrlCrossRefPubMed
  37. ↵
    1. Weihe E,
    2. Leibold A,
    3. Nohr D,
    4. Gauweiler B
    (1986) Co-existence of prodynorphin-opioid peptides and substance P in primary sensory afferents of guinea-pig. NIDA Res Monogr 75:295–298.
    OpenUrlPubMed
  38. ↵
    1. Weihe E,
    2. Millan MJ,
    3. Hollt V,
    4. Nohr D,
    5. Herz A
    (1989) Induction of the gene encoding pro-dynorphin by experimentally induced arthritis enhances staining for dynorphin in the spinal cord of rats. Neuroscience 31:77–95.
    OpenUrlCrossRefPubMed
  39. ↵
    1. Willcockson WS,
    2. Kim J,
    3. Shin HK,
    4. Chung JM,
    5. Willis WD
    (1986) Actions of opioids on primate spinothalamic tract neurons. J Neurosci 6:2509–2520.
    OpenUrlAbstract
  40. ↵
    1. Herz A
    1. Yaksh TL
    (1993) The spinal actions of opioids. in Opioids II, Handbook of Experimental Pharmacology, ed Herz A (Springer-Verlag, Berlin), 104/II:53–90.
  41. ↵
    1. Zhang K-M,
    2. Wang X-M,
    3. Mokha SS
    (1996) Opioids modulate N-methyl-D-aspartic acid (NMDA)-evoked responses of neurons in the superficial and deeper dorsal horn of the medulla (trigeminal nucleus caudalis). Brain Res 719:229–233.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools
OtherNEUROPHARMACOLOGY

Dynorphin Block of N-Methyl-d-Aspartate Channels Increases with the Peptide Length

Li Chen and Li-Yen Mae Huang
Journal of Pharmacology and Experimental Therapeutics March 1, 1998, 284 (3) 826-831;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section